Epstein Secrets

Jane Doe No. 1 and Jane Doe No. 2 became familiar enough with the non-prosecution agreement to both invoke its provisions in their lawsuits against Jeffrey Epstein under 18 U.S.C. § 2255.1 United States' Reply in Support of Its Motion to Dismiss for Lack of Subject matter Jurisdiction, D.E. 205-6, Exhibits A -

wsuit was that the government failed to consult with them prior to what they believed would be the disposition of the federal investigation against Epstein. D.E. I II 3,4. They knew, at the time their petition was filed, that Epstein had "recently been prosecuted and pleaded guilty, on June 30, 2008, i

h invoke its provisions in their lawsuits against Jeffrey Epstein under 18 U.S.C. § 2255.1 United States'

) (CVRA was a legislative compromise enacted after an attempt to pass a constitutional amendment protecting victims' rights failed)• United States'. Alcatel-Lucent France. SA, 688 F.3d 1301, 1305 (11'h Cir.) ("[G]enerally a citizen lacks standing to contest the policies of a prosecuting attorney when the citiz

of Linkedln Connections <[email protected]> Sent: Tue 7/30/2013 12:48:46 PM Subject: See Jonathon's connections, experience, and more... Jeffrey, Jonathon has accepted your invitation. Jonathon Farkas board member at united nations development corporation United States View Jonathon's P

mpany J.P. Morgan \I Follow Company This is an occasional email to help you get the most out of Linkedin Unsubsenbe This email was intended for Jeffrey Epstein. Learn why we included this -- 2013. Linkedln Corporation. 2029 Sherbn Ct. Mountain View, CA 94043. USA EPTA_R1_004 37372 EFTA01962167

To: Jeffrey Epstein[[email protected]] From: messages-noreply@b

Executive Assistant at DKIPLLC Connect )';'", ( I • LTE Focus Join ,OMPANIES IN JONATHON'S NETWORK UBS Wealth Management Follow Company • Alcatel-Lucent • Follow Company EFTA_R1_00437371 EFTA01962166 —t Oracle Follow Company J.P. Morgan \I Follow Company This is an occasional email to help

tlev Engel Klaus Engel Richard P. Eno David R. Epstein Mary Callahan Erdoes Charles W. Ergen Paula E

kil Beshir Ulrich L. Bettermann Erik Behermann Jeffrey L. Bewkes Donald S. Beyer Homi K. Bhabha Neera

e Capital Nature KPMG SWIFT SCRL Merck 8 Co. Inc. HCL Axon Centrica Plc Jose Carreras International Leukaemia Foundation Anglo American Plc Alcatel-Lucent CNBC Mashable Sace SpA Atlantia SpA Grupo Prisa NYSE Euronext HSBC Asia Pacific PepsiCo India Holdings Pvt. Ltd Cisco Morgan Stanley Inter

Chief Executive Officer Metabolix USA David R. Epstein Head. Pharma Division Novartis AG Switzerland

rman of the Board OBO Bettermann Group Germany Jeffrey L. Bewkes Chairman and Chief Executive Officer

Spain Leukaemia Foundation Cynthia Carroll Chief Executive Anglo American Plc United Kingdom Stephen A. Carter Chief Marketing, Strategy and Alcatel-Lucent France Communication Officer and Executive Vice-President Jaime Caruana General Manager, Bank for International Settlements (BIS), Basel John

Chief Executive Officer Metabolix USA David R. Epstein Head. Pharma Division Novartis AG Switzerland

rman of the Board OBO Bettermann Group Germany Jeffrey L. Bewkes Chairman and Chief Executive Officer

Spain Leukaemia Foundation Cynthia Carroll Chief Executive Anglo American Plc United Kingdom Stephen A. Carter Chief Marketing, Strategy and Alcatel-Lucent France Communication Officer and Executive Vice-President Jaime Caruana General Manager, Bank for International Settlements (BIS), Basel John

rld Economic Forum Annual Meeting 2011 Merck & Co. Inc. HCL Axon Centrica Plc José Carreras International Leukaemia Foundation Anglo American Plc Alcatel-Lucent CNBC Mashable Sace SpA Atlantia SpA Grupo Prisa NYSE Euronext HSBC Asia Pacific PepsiCo India Holdings Pvt. Ltd Cisco Morgan Stanley Internati

tlev Engel Klaus Engel Richard P. Eno David R. Epstein Mary Callahan Erdoes Charles W. Ergen Paula Esco